retatrutide study sign up Eli Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide—A Game Changer in Obesity

Tirzepatide users were less likely to experience any major cardiovascular problems following surgery than people not on the drug (roughly 30% lower risk), though the rate of some problems like heart attacks remained roughly the same between the two groups

Surgical procedures like bariatric surgery often lead to more rapid weight loss but come with different risks and benefits, so consulting with a physician who is well-versed in both options can help you decide which is right for your goals

Nevertheless, Kumarathurai et al

Predictors for repeated hyperkalemia and potassium trajectories in high risk patientsa population-based cohort study

40g protein, under 400 calories, packed with fiber to support digestion and satiety

To reduce symptoms, patients can try eating smaller meals throughout the day, avoiding high-fat or fried foods, and drinking plenty of water